<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621437</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL14_0456</org_study_id>
    <nct_id>NCT02621437</nct_id>
  </id_info>
  <brief_title>Impact of Osteopathy on Pain After Breast Cancer Surgery</brief_title>
  <acronym>IPOD</acronym>
  <official_title>Study of the Impact of Osteopathic Care, Complementary Therapy to Standard Care, on Pain in Patients With Breast Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer can be painful following surgery or can develop later and remain persistent.&#xD;
      Pain occurrence is frequent with 50% of women developing sequelae pain of varying intensity&#xD;
      with an impact on the quality of life. One of the priorities of the 3rd French Cancer Plan is&#xD;
      to preserve quality of life.&#xD;
&#xD;
      Osteopathy, complementary therapy, may help to reduce inconvenience caused by the disease,&#xD;
      treatments and their side effects (asthenia, anxiety and pain).&#xD;
&#xD;
      The main objective is to assess the impact of osteopathic treatment on pain in patients&#xD;
      following breast cancer surgery. The impact will be considered beneficial if the pain score&#xD;
      (digital scale) in the intervention group is lower, by at least two points, than the pain&#xD;
      score in the control group at the end of the study.&#xD;
&#xD;
      This is a monocentric, randomized, parallel group, single-blind and prospective clinical&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the impact of osteopathic treatment on pain in patients following breast cancer surgery</measure>
    <time_frame>at Day 9</time_frame>
    <description>The primary outcome measure will be the evaluation of the &quot;usual pain in the last eight days&quot; measured from the pain score (digital scale). The pain score consists of asking the patient to quantify her pain on a virtual scale from 0 (absent pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the impact of osteopathic treatment on pain in patients following breast cancer surgery</measure>
    <time_frame>at day 20</time_frame>
    <description>The primary outcome measure will be the evaluation of the &quot;usual pain in the last eight days&quot; measured from the pain score (digital scale). The pain score consists of asking the patient to quantify her pain on a virtual scale from 0 (absent pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the impact of osteopathic treatment on pain in patients following breast cancer surgery</measure>
    <time_frame>at day 26</time_frame>
    <description>The primary outcome measure will be the evaluation of the &quot;usual pain in the last eight days&quot; measured from the pain score (digital scale). The pain score consists of asking the patient to quantify her pain on a virtual scale from 0 (absent pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the impact of osteopathic treatment on pain in patients following breast cancer surgery</measure>
    <time_frame>at Day 34</time_frame>
    <description>The primary outcome measure will be the evaluation of the &quot;usual pain in the last eight days&quot; measured from the pain score (digital scale). The pain score consists of asking the patient to quantify her pain on a virtual scale from 0 (absent pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the impact of osteopathic treatment on pain in patients following breast cancer surgery</measure>
    <time_frame>at Day 40</time_frame>
    <description>The primary outcome measure will be the evaluation of the &quot;usual pain in the last eight days&quot; measured from the pain score (digital scale). The pain score consists of asking the patient to quantify her pain on a virtual scale from 0 (absent pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the impact of osteopathic treatment on pain in patients following breast cancer surgery</measure>
    <time_frame>at Day 48</time_frame>
    <description>The primary outcome measure will be the evaluation of the &quot;usual pain in the last eight days&quot; measured from the pain score (digital scale). The pain score consists of asking the patient to quantify her pain on a virtual scale from 0 (absent pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the quality of life in patients who have been operated on breast cancer.</measure>
    <time_frame>at day 9</time_frame>
    <description>Assessment of quality of life by the SF-12 questionnaire, which is a shortened version of the &quot; Medical Outcomes Study Short-Form General Health Survey &quot; (SF-36), comprising only 12 of the 36 issues. The SF-12 is used to calculate two scores, which measure the functional health and well-being of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the quality of life in patients who have been operated on breast cancer.</measure>
    <time_frame>at day 20</time_frame>
    <description>Assessment of quality of life by the SF-12 questionnaire, which is a shortened version of the &quot; Medical Outcomes Study Short-Form General Health Survey &quot; (SF-36), comprising only 12 of the 36 issues. The SF-12 is used to calculate two scores, which measure the functional health and well-being of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the quality of life in patients who have been operated on breast cancer.</measure>
    <time_frame>at day 26</time_frame>
    <description>Assessment of quality of life by the SF-12 questionnaire, which is a shortened version of the &quot; Medical Outcomes Study Short-Form General Health Survey &quot; (SF-36), comprising only 12 of the 36 issues. The SF-12 is used to calculate two scores, which measure the functional health and well-being of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the quality of life in patients who have been operated on breast cancer.</measure>
    <time_frame>at day 34</time_frame>
    <description>Assessment of quality of life by the SF-12 questionnaire, which is a shortened version of the &quot; Medical Outcomes Study Short-Form General Health Survey &quot; (SF-36), comprising only 12 of the 36 issues. The SF-12 is used to calculate two scores, which measure the functional health and well-being of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the quality of life in patients who have been operated on breast cancer.</measure>
    <time_frame>at day 40</time_frame>
    <description>Assessment of quality of life by the SF-12 questionnaire, which is a shortened version of the &quot; Medical Outcomes Study Short-Form General Health Survey &quot; (SF-36), comprising only 12 of the 36 issues. The SF-12 is used to calculate two scores, which measure the functional health and well-being of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the quality of life in patients who have been operated on breast cancer.</measure>
    <time_frame>at day 48</time_frame>
    <description>Assessment of quality of life by the SF-12 questionnaire, which is a shortened version of the &quot; Medical Outcomes Study Short-Form General Health Survey &quot; (SF-36), comprising only 12 of the 36 issues. The SF-12 is used to calculate two scores, which measure the functional health and well-being of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the reduction of anxiety of patients operated for breast cancer.</measure>
    <time_frame>at Day 9</time_frame>
    <description>Assessment of anxiodepressive disorders from the HAD scale (Hospital and Anxiety Depression), each response is rated from 0-3 on a scale evaluating semi-quantitatively the intensity of symptoms during the past week. This study will use just the score of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the reduction of anxiety of patients operated for breast cancer.</measure>
    <time_frame>at Day 20</time_frame>
    <description>Assessment of anxiodepressive disorders from the HAD scale (Hospital and Anxiety Depression), each response is rated from 0-3 on a scale evaluating semi-quantitatively the intensity of symptoms during the past week. This study will use just the score of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the reduction of anxiety of patients operated for breast cancer.</measure>
    <time_frame>at Day 26</time_frame>
    <description>Assessment of anxiodepressive disorders from the HAD scale (Hospital and Anxiety Depression), each response is rated from 0-3 on a scale evaluating semi-quantitatively the intensity of symptoms during the past week. This study will use just the score of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the reduction of anxiety of patients operated for breast cancer.</measure>
    <time_frame>at Day 34</time_frame>
    <description>Assessment of anxiodepressive disorders from the HAD scale (Hospital and Anxiety Depression), each response is rated from 0-3 on a scale evaluating semi-quantitatively the intensity of symptoms during the past week. This study will use just the score of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the reduction of anxiety of patients operated for breast cancer.</measure>
    <time_frame>at Day 40</time_frame>
    <description>Assessment of anxiodepressive disorders from the HAD scale (Hospital and Anxiety Depression), each response is rated from 0-3 on a scale evaluating semi-quantitatively the intensity of symptoms during the past week. This study will use just the score of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of osteopathic treatment on the reduction of anxiety of patients operated for breast cancer.</measure>
    <time_frame>at Day 48</time_frame>
    <description>Assessment of anxiodepressive disorders from the HAD scale (Hospital and Anxiety Depression), each response is rated from 0-3 on a scale evaluating semi-quantitatively the intensity of symptoms during the past week. This study will use just the score of anxiety.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention group (osteopathy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have three sessions of osteopathy and 6 phone questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will have 6 phone questionnaires.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Osteopathy sessions</intervention_name>
    <description>- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),</description>
    <arm_group_label>Intervention group (osteopathy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>phone questionnaires</intervention_name>
    <description>Six phone questionnaires (D9, D20, D26, D34, D40 and D48):&#xD;
pain questionnaire with digital scale,&#xD;
quality of life survey: SF-12&#xD;
HAD (Hospital and Anxiety Depression) questionnaire</description>
    <arm_group_label>Intervention group (osteopathy)</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult woman&#xD;
&#xD;
          -  Surgery for a malignant breast tumor with sentinel lymph node technique&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under-age women&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Surgery for a malignant breast tumor with lymph node dissection&#xD;
&#xD;
          -  Receiving adjuvant therapy during the study&#xD;
&#xD;
          -  Receiving physiotherapy sessions (other than those made in immediate post-operative)&#xD;
&#xD;
          -  Participating in the space &quot;Au Fil de Soi&quot;: relaxing body massage and Energy Resonance&#xD;
             by Cutaneous Stimulation (RESC)&#xD;
&#xD;
          -  Person under guardianship or supervision&#xD;
&#xD;
          -  Patient with impaired cognitive functions or lack of understanding of the French&#xD;
             language&#xD;
&#xD;
          -  Presenting a contraindication for osteopathy (major infectious and inflammatory&#xD;
             conditions, trauma and other severe diseases)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil DUBERNARD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de gyn√©cologie</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>quality of life</keyword>
  <keyword>osteopathy</keyword>
  <keyword>oncology</keyword>
  <keyword>surgery</keyword>
  <keyword>breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

